SRSF9

Across TCGA pan-cancer cohorts, SRSF9 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SRSF9 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SRSF9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SRSF9 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where SRSF9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.882	0.499	.003	37	view →
CCRCC	DFS	Quartile	III,IV	0.250	0.741	.001	35	view →
LUAD	OS	Median	II,III,IV	0.845	0.484	.002	32	view →
PDAC	DFS	Median	III,IV	0.219	0.498	.025	7	view →
HNSC	OS	Quartile	All	0.665	0.885	.021	7	view →
UCEC	OS	Median	All	0.909	0.982	.023	6	view →
GBM	DFS	Median	All	0.331	0.199	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SRSF9–LSCC (DFS)

Open the LSCC breakdown →